Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $1.0 billion.

  • ImmunityBio's Total Liabilities fell 598.3% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 598.3%. This contributed to the annual value of $871.1 million for FY2024, which is 2011.46% down from last year.
  • Latest data reveals that ImmunityBio reported Total Liabilities of $1.0 billion as of Q3 2025, which was down 598.3% from $971.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Total Liabilities ranged from a high of $1.1 billion in Q2 2024 and a low of $394.8 million during Q1 2021
  • For the 5-year period, ImmunityBio's Total Liabilities averaged around $833.9 million, with its median value being $871.1 million (2024).
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 151603.08% in 2021, then plummeted by 2011.46% in 2024.
  • Over the past 5 years, ImmunityBio's Total Liabilities (Quarter) stood at $712.8 million in 2021, then rose by 13.94% to $812.2 million in 2022, then surged by 34.26% to $1.1 billion in 2023, then decreased by 20.11% to $871.1 million in 2024, then rose by 19.67% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $971.9 million for Q2 2025, and $894.2 million during Q1 2025.